S&P 500 Futures
(0.21%) 5 142.50 points
Dow Jones Futures
(0.08%) 38 471 points
Nasdaq Futures
(0.36%) 17 910 points
Oil
(-0.64%) $83.31
Gas
(1.40%) $1.950
Gold
(-0.26%) $2 341.20
Silver
(-0.14%) $27.50
Platinum
(2.53%) $945.45
USD/EUR
(-0.15%) $0.933
USD/NOK
(-0.12%) $11.01
USD/GBP
(-0.32%) $0.798
USD/RUB
(1.34%) $93.10

Echtzeitaktualisierungen für Prescient Therapeutics [PTX.AX]

Börse: ASX Industrie: Pharmaceuticals, Biotechnology & Life Sciences
Zuletzt aktualisiert29 Apr 2024 @ 08:10

0.00% $ 0.0520

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 08:10):
Profile picture for Prescient Therapeutics Ltd

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations...

Stats
Tagesvolumen 762 848
Durchschnittsvolumen 1.17M
Marktkapitalisierung 41.88M
EPS $0 ( 2024-02-21 )
Last Dividend $7.15 ( 1993-10-21 )
Next Dividend $0 ( N/A )
P/E -5.20
ATR14 $0.00100 (1.89%)

Prescient Therapeutics Korrelation

10 Am meisten positiv korreliert
10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Prescient Therapeutics Finanzdaten

Annual 2023
Umsatz: $2.43M
Bruttogewinn: $2.43M (99.91 %)
EPS: $-0.00960
FY 2023
Umsatz: $2.43M
Bruttogewinn: $2.43M (99.91 %)
EPS: $-0.00960
FY 2022
Umsatz: $1.89M
Bruttogewinn: $1.89M (99.93 %)
EPS: $-0.00790
FY 2021
Umsatz: $0.00
Bruttogewinn: $0.00 (0.00 %)
EPS: $-0.00680

Financial Reports:

No articles found.

Prescient Therapeutics Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Prescient Therapeutics Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future
Information
First Dividend $5.72 1990-10-25
Last Dividend $7.15 1993-10-21
Next Dividend $0 N/A
Payout Date 1993-12-31
Next Payout Date N/A
# dividends 2 --
Total Paid Out $12.87 --
Avg. Dividend % Per Year 0.00% --
Score 0.22 --
Div. Sustainability Score 0
Div.Growth Potential Score 0
Div. Directional Score 0 --
Next Divdend (Est)
(2026-10-05)
$0 Estimate 0.00 %
Dividend Stability
0.00 Very Bad
Dividend Score
0.22
Pay Frequency
Sporadic
Yearly Payout
Year Amount Yield

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for ASX

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
WAM.AX Ex Dividend Knight 2023-10-17 Semi-Annually 0 0.00%
EGG.AX Ex Dividend Knight 2023-09-19 Semi-Annually 0 0.00%
PBH.AX No Dividend Player 2023-09-06 Insufficient data to determine frequency 0 0.00%
ALL.AX Ex Dividend Knight 2023-05-25 Annually 0 0.00%
GOZ.AX Ex Dividend Junior 2023-06-29 Semi-Annually 0 0.00%
REH.AX Ex Dividend Knight 2023-10-10 Semi-Annually 0 0.00%
BOQ.AX Ex Dividend Junior 2023-05-10 Annually 0 0.00%
KPG.AX Ex Dividend Knight 2023-07-20 Monthly 0 0.00%
SPK.AX Ex Dividend Knight 2023-09-14 Semi-Annually 0 0.00%
COF.AX Ex Dividend Junior 2023-09-28 Quarterly 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM-2.491.500-10.00-10.00[0 - 0.5]
returnOnAssetsTTM-0.3131.200-10.00-10.00[0 - 0.3]
returnOnEquityTTM-0.3181.500-4.65-6.97[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM10.260.80010.008.00[1 - 3]
quickRatioTTM9.960.80010.008.00[0.8 - 2.5]
cashRatioTTM3.081.50010.0010.00[0.2 - 2]
debtRatioTTM0-1.50000[0 - 0.6]
interestCoverageTTM01.000-1.111-1.111[3 - 30]
operatingCashFlowPerShareTTM-0.009522.00-0.00317-0.00635[0 - 30]
freeCashFlowPerShareTTM-0.009522.00-0.00476-0.00952[0 - 20]
debtEquityRatioTTM0-1.50000[0 - 2.5]
grossProfitMarginTTM1.0001.00010.0010.00[0.2 - 0.8]
operatingProfitMarginTTM-3.711.000-10.00-10.00[0.1 - 0.6]
cashFlowToDebtRatioTTM01.000-1.111-1.111[0.2 - 2]
assetTurnoverTTM0.1260.800-2.50-1.996[0.5 - 2]
Total Score-0.920

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-5.511.000-0.6580[1 - 100]
returnOnEquityTTM-0.3182.50-2.99-6.97[0.1 - 1.5]
freeCashFlowPerShareTTM-0.009522.00-0.00317-0.00952[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-0.009522.00-0.00317-0.00635[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM-1.9111.500-10.000[0.5 - 2]
operatingCashFlowSalesRatioTTM-2.461.000-10.000[0.1 - 0.5]
Total Score-2.81

Prescient Therapeutics

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.

Über Live-Signale

Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.

Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.